Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.

Int J Colorectal Dis · 2024 · PMC11511701 · PMID 39453531

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

did not reach statistical significanceP = 0.085so close (0.05 < p ≤ 0.1)

Although the difference did not reach statistical significance ( P = 0.085), patients in the “PTR” group demonstrated a trend of more favorable outcome.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.